Oppenheimer Reiterates Outperform on ESSA Pharma, Maintains $17 Price Target
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Mark Breidenbach has reiterated an Outperform rating on ESSA Pharma (NASDAQ:EPIX) and maintained a price target of $17.
December 13, 2023 | 4:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer analyst Mark Breidenbach has reiterated an Outperform rating on ESSA Pharma and maintained a $17 price target.
The reiteration of an Outperform rating and the maintenance of a $17 price target by a reputable analyst like Mark Breidenbach could lead to increased investor confidence in ESSA Pharma, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100